ImmuOn Therapeutics is founded by oversea returned scientists and is a fully integrated biopharma company.
ImmuOn is one of the few biotech companies in China who first explored immunotherapy and related products.
Currently we focus at research and development of preventive and therapeutic vaccines for adult population.
Among several different forms of immunotherapies, recombinant antigen based vaccine has its unique advantages.
Besides its suitability for mass production at low cost, it’s also easy to store and to transport and simple to administrate.
For a populated country like China, vaccine based immunotherapy has both economic and social importance.
The major research and development pipeline of ImmuOn includes preventive and therapeutic vaccines against
oncoviruses and cancer therapeutic vaccines based on neoantigens. Our proprietary technology platform “MixShot”
provides a solution for issues such as screening and preparation of vaccines for personalized cancer immunotherapy.
It can be used for both cancer vaccine research as well as new product development.
Our team includes achieved scientists in vaccine research who had worked before for major international
pharmaceutical companies such as AstraZeneca, Chiron、Merck, Novartis, Genezyme。
We believe that immunotherapy will enter a fruitful new era with broad international collaboration and effort.